Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants

Journal of Virology

Volumn 72, Issue 5, 1998, Pages 3520-3523

  Yerly, Sabine ^a   Rakik, Abdelrahim ^a   De Loes, Sabine Kinloch ^a   Hirschel, Bernard ^a   Descamps, Diane ^b   Brun Vézinet, Françoise ^b   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SEQUENCE; ARTICLE; CODON; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; VIRUS CULTURE; VIRUS INFECTION; VIRUS ISOLATION;

EID: 0031977656     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.5.3520-3523.1998     Document Type: Article

References (32)

1. Albert, J., J. Wahlberg, J. Lundeberg, S. Cox, E. Sadstrom, B. Wahren, and M. Uhlen. 1992. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J. Virol. 66:5627-5630.
2. Boucher, C. A., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Boucher, C. A., R. van Leeuven, P. Kellam, P. Schipper, J. Tijnagel, J. M. Lange, and B. A. Larder. 1993. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1525-1530.
4. Brun-Vezinet, F., D. Ingrand, L. Desforges, K. Gochi, F. Ferchal, M. P. Schmitt, M. Jung, B. Masquelier, J. Aubert, C. Buffet-Janvresse, and H. Fleury. 1992. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods 37:177-188.
5. Coffin, J. M. 1995. HIV population dynamics in vivo: implication for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
7. De Ronde, A., R. Schuurman, J. Goudsmit, A. van den Hoek, and C. A. Boucher. 1996. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. AIDS 10:231-232.
8. Goudsmit, J., A. de Ronde, E. de Rooij, and R. Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
9. Harrigan, P. R., S. Bloor, and B. A. Larder. 1996. Quantitation of viral fitness and AZT selection pressure of AZT resistant HIV-1 variants. Antivir. Ther. 1(Suppl. 1):55.
10. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virion and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
11. Hollinger, F. B. (ed.). 1993. ACTG virology manual for HIV laboratories, 2nd ed. U.S. Public Health Service publication no. NIH-94-3828. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
12. Imrie, A., A. Carr, C. Duncombe, R. Finlayson, J. Vizzard, M. Law, J. Kaldor, R. Penny, D. A. Cooper, and the Sydney Primary HIV Infection Study Group. 1996. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. J. Infect. Dis. 174:195-198.
13. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, and D. R. Kuritzkes. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
14. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
15. Keulen, W., C. A. Boucher, and B. Berkhout. 1996. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res. 31:45-57.
16. Kinloch-de Loes, S., B. Hirschel, B. Hoen, D. A. Cooper, B. Tindall, A. Carr, J. H. Saurat, N. Clumeck, A. Lazzarin, L. Mathiesen, F. Raffi, F. Antunes, J. von Overbeck, R. Luthy, M. Glauser, D. Hawkins, C. Baumberger, S. Yerly, T. V. Perneger, and L. Perrin. 1995. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N. Engl. J. Med. 333:408-413.
17. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV-1 with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
18. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
19. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HTV-infected lymphocytes. AIDS 5:137-144.
20. Leigh Brown, A. J., and D. D. Richman. 1997. HIV-1: gambling on the evolution of drug resistance? Nat. Med. 3:268-271.
21. Mayers, D. L., S. Yerly, L. Perrin, A. Imrie, D. A. Cooper, W. W. Karney, A. E. Brown, A. Rakik, R. Harris, J. Gambel, O. S. Weislow, J. L. Lennox, and D. S. Burke. 1994. Prevalence of AZT-resistant HIV-1 in persons sero-converting in Switzerland, Australia, and the United States between 1988 and 1994. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Mohri, H., M. K. Singh, W. T. Ching, and D. D. Ho. 1993. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. USA 90:25-29.
23. Najera, I., A. Holguin, M. E. Quinones-Mateu, M. A. Munoz-Fernandez, R. Najera, C. Lopez-Galindez, and E. Domingo. 1995. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
24. Quigg, M., S. Rebus, A. J. France, J. McMenamin, G. Darby, and A. J. Leigh Brown. 1997. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS 11:835-836.
25. Quinones-Mateu, M. E., A. Holguin, J. Dopazo, I. Najera, and E. Domingo. 1996. Point mutation frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Res. Hum. Retroviruses 12:1117-1128.
26. Schwartz, O., Y. Henin, V. Marechal, and L. Montagnier. 1988. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res. Hum. Retroviruses 4:441-448.
27. Smith, M. S., K. L. Koerber, and J. S. Pagano. 1994. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J. Infect. Dis. 169:184-188.
28. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in HIV-1 infection. Nature 373:117-122.
29. Wong, J. K., C. C. Ignacio, F. Torriani, D. Havlir, N. J. S. Fitch, and D. D. Richman. 1997. In vivo compartmentalization of human immunodeficiency virus: evidence from examination of pol sequences from autopsy tissues. J. Virol. 71:2059-2071.
30. Yerly, S., N. Denereaz, B. Mermillod, B. Hirschel, and L. Perrin. 1996. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients. Antiviral Ther. 1:167-171.
31. Yerly, S., A. Rakik, S. Kinloch-de Loes, P. Erb, P. Vernazza, B. Hirschel, and L. Perrin. 1996. Prévalence de la transmission de virus résistant à la zidovudine en Suisse. Schweiz. Med. Wochenschr. 126:1845-1848.
32. Zhang, L. Q., P. Simmonds, C. A. Ludlam, and A. J. Leigh Brown. 1991. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS 5:675-681.